Alnylam Pharma (ALNY) Announces Positive Fitusiran Phase 1 Data as Hemophilia and Rare Bleeding Disorders Treatment
Go back to Alnylam Pharma (ALNY) Announces Positive Fitusiran Phase 1 Data as Hemophilia and Rare Bleeding Disorders Treatment| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 143.71 -0.09 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.80 | 52 Week High | $109.10 | |||
| Open | $143.00 | 52 Week Low | $31.38 | |||
| Day High | $145.79 | P/E | N/A | |||
| Day Low | $141.98 | EPS | $-1.45 | |||
| Volume | 489,265 | |||||
